For U.S. Big Pharma companies, vaccines have largely been an afterthought. But by 2030, they could be a quarter of Pfizer’s revenue.
Brown’s Giuliani RNA Center and the Rhode Island Life Science Hub co-hosted a symposium focused on how scientists can work ...
The Flu RNA Vaccines Market offers transformative opportunities driven by rapid development, adaptability, and potential ...
Yet not all large-scale research into mRNA vaccines in the United States is being dismantled. Nature has learnt that, even as ...
A biotech that lost federal funding Tuesday following Health Secretary Robert F. Kennedy Jr.’s edict that his agency’s pandemic preparedness division stop funding development of messenger RNA-based ...
The promise of messenger RNA (mRNA) has moved far beyond its pandemic-era spotlight. In oncology, mRNA has emerged as a ...
According to DataM Intelligence, "The RNA-Based Therapies Market Size, valued at USD 90.56 billion in 2024, is projected to ...
Oncologists and scientists warn that extensive cuts to mRNA funding will have devastating impacts on cancer vaccine ...
SAN FRANCISCO -- As more people are getting vaccinated, medical experts in the United Kingdom and the U.S are holding trials to find out if giving two doses of a different COVID vaccine improves your ...
To solve a problem, scientists first need to see it clearly. Whether it’s a virus slipping past the immune system or plaques ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback